share_log

醫思健康:2024/25 半年度業績報告

EC HEALTHCARE: INTERIM REPORT 2024/25

HKEX ·  Dec 20 16:57

Summary by Futu AI

醫思健康公佈截至2024年9月30日止六個月中期業績。期內收入下降2.8%至20.63億港元,主要受宏觀經濟環境影響。淨利潤大幅增長88.1%至4030萬港元,每股基本盈利1.2港仙。醫療服務收入下降3.7%至12.64億港元,美學醫療及美容養生服務收入下降5.4%至6.30億港元,獸醫及其他服務收入增長18.9%至1.69億港元。集團積極應對市場挑戰,採取多項措施提升營運效率。包括優化新設服務點營運、總部成本控制、利息開支管理等。同時加強B2B、B2I及B2G業務機會,提升服務網絡互聯互通。集團亦審慎管理營運資金,實施重大成本重組,包括減少員工、優化租賃等。展望未來,集團對香港醫療市場保持審慎樂觀。將聚焦三大領域實現利潤增長:業務發展、卓越營運及數字化轉型。集團將利用平台方法創造相關產品,提升人才生產力和資產利用率,並加強數字化能力。同時將繼續尋求戰略併購機會,優化資產組合,為股東創造長期價值。
醫思健康公佈截至2024年9月30日止六個月中期業績。期內收入下降2.8%至20.63億港元,主要受宏觀經濟環境影響。淨利潤大幅增長88.1%至4030萬港元,每股基本盈利1.2港仙。醫療服務收入下降3.7%至12.64億港元,美學醫療及美容養生服務收入下降5.4%至6.30億港元,獸醫及其他服務收入增長18.9%至1.69億港元。集團積極應對市場挑戰,採取多項措施提升營運效率。包括優化新設服務點營運、總部成本控制、利息開支管理等。同時加強B2B、B2I及B2G業務機會,提升服務網絡互聯互通。集團亦審慎管理營運資金,實施重大成本重組,包括減少員工、優化租賃等。展望未來,集團對香港醫療市場保持審慎樂觀。將聚焦三大領域實現利潤增長:業務發展、卓越營運及數字化轉型。集團將利用平台方法創造相關產品,提升人才生產力和資產利用率,並加強數字化能力。同時將繼續尋求戰略併購機會,優化資產組合,為股東創造長期價值。
EC HEALTHCARE announced its interim results for the six months ending September 30, 2024. During the period, revenue decreased by 2.8% to 2.063 billion HKD, mainly affected by the macroeconomic environment. Net profit surged by 88.1% to 40.3 million HKD, with basic earnings per share at 1.2 HKD cents. Revenue from Veterinary Services decreased by 3.7% to 1.264 billion HKD, while revenue from aesthetic medical and wellness services fell by 5.4% to 0.63 billion HKD. Revenue from veterinary and Other services grew by 18.9% to 0.169 billion HKD.The group actively responds to market challenges and has implemented various measures to enhance operational efficiency. This includes optimizing the operation of new service points, controlling headquarters costs, and managing interest expenses. At the same time, it strengthens B2B, B2I, and B2G business opportunities to enhance the connectivity...Show More
EC HEALTHCARE announced its interim results for the six months ending September 30, 2024. During the period, revenue decreased by 2.8% to 2.063 billion HKD, mainly affected by the macroeconomic environment. Net profit surged by 88.1% to 40.3 million HKD, with basic earnings per share at 1.2 HKD cents. Revenue from Veterinary Services decreased by 3.7% to 1.264 billion HKD, while revenue from aesthetic medical and wellness services fell by 5.4% to 0.63 billion HKD. Revenue from veterinary and Other services grew by 18.9% to 0.169 billion HKD.The group actively responds to market challenges and has implemented various measures to enhance operational efficiency. This includes optimizing the operation of new service points, controlling headquarters costs, and managing interest expenses. At the same time, it strengthens B2B, B2I, and B2G business opportunities to enhance the connectivity of the service network. The group also prudently manages operational funds, undertaking significant cost restructuring, including employee reductions and optimizing leases.Looking ahead, the group remains cautiously optimistic about the Hong Kong healthcare market. It will focus on three major areas to achieve profit growth: Business development, operational excellence, and digital transformation. The group will utilize a platform approach to create relevant products, enhance talent productivity and Asset utilization, and strengthen digital capabilities. At the same time, it will continue to seek strategic merger and acquisition opportunities, optimize the asset portfolio, and create long-term value for Shareholders.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.